Roe Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Roe Next-Generation Sequencing (NGS) Services Market was valued at $58.7 Million in 2017 and projected to reach to $152.1 Million by 2022, representing a compound annual growth rate of CAGR 21.0%. Roe's NGS services market is positioned for sustained growth as healthcare providers increasingly recognize the clinical and economic value of genomic sequencing.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Roe Next-Generation Sequencing (NGS) Services Market Trends and Insights
- This 21.0% compound annual growth rate reflects Roe's increasing adoption of advanced genomic technologies across clinical diagnostics, research institutions, and pharmaceutical development.
- Roe's market growth is driven by rising healthcare investments, growing prevalence of genetic disorders, and expanding precision medicine initiatives throughout the region. The NGS services landscape in Roe is characterized by accelerating demand for cost-effective sequencing solutions and enhanced diagnostic capabilities.
- Roe's healthcare infrastructure continues to modernize, with laboratories and medical centers integrating NGS platforms to improve patient outcomes and enable personalized treatment strategies.
- The market's trajectory from 2017 to 2022 underscores Roe's commitment to genomic innovation and its position as a growing hub for molecular diagnostics within Europe..
Key Market Statistics
- CAGR (2017-2022) CAGR 21.0%
- Market Size, 2017 ~USD 58.7 Million
- Forecast, 2022 ~USD 152.1 Million
- Country Roe
Roe Next-Generation Sequencing (NGS) Services Market Overview
Exceptional Growth Trajectory :
Roe's NGS services market experienced a remarkable 21% CAGR from 2017 to 2022, demonstrating strong market momentum and increasing healthcare investment in genomic technologies.
Significant Market Expansion :
Market size grew from $58.7 million in 2017 to $152.1 million by 2022, representing a 159% increase over five years and indicating accelerating adoption of sequencing services.
Clinical Diagnostics Leadership :
Roe's healthcare institutions are increasingly integrating NGS into clinical diagnostics, driving demand for advanced sequencing services across oncology, rare disease identification, and personalized medicine.
Research & Pharma Investment :
Growing pharmaceutical development and research institution investments in Roe are fueling NGS service adoption for drug discovery, biomarker identification, and genomic research initiatives.
Roe Next-Generation Sequencing (NGS) Services Market Dynamics
- The 21% CAGR trajectory suggests continued expansion driven by declining sequencing costs, regulatory support for precision medicine, and growing awareness among clinicians and patients.
- Investment in genomic infrastructure and skilled workforce development will further accelerate market penetration across Roe's healthcare ecosystem. Looking ahead, Roe's market will likely benefit from integration of NGS into standard diagnostic protocols, expansion of liquid biopsy applications, and increased adoption in preventive healthcare.
- Partnerships between local healthcare systems and international sequencing providers, combined with government initiatives supporting genomic medicine, are expected to sustain the 21% growth rate through the forecast period and beyond..
Market Ecosystem
NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Scientists studying Usutu virus sent viral nucleic acid to Eurofins Genomics for a dedicated RNA-virus sequencing service (INVIEW virus sequencing) on an Illumina NovaSeq 6000 to generate whole-genome data for analysis and comparison with other methods | Quick access to high-quality viral genomes | High-throughput sequencing without adding lab capacity | Supports surveillance and phylogenetics | Clean data for downstream bioinformatics |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Roe's NGS Services Market is projected to grow from $58.7M (2017) to $152.1M (2022), representing a 21.0% CAGR.
- Roe demonstrates strong market momentum driven by precision medicine adoption and increased genomic research funding.
- Roe's healthcare sector is investing heavily in NGS infrastructure to enhance diagnostic accuracy and clinical outcomes.
- Roe's competitive landscape is expanding with both established and emerging sequencing service providers entering the market.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Roe Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Healthcare Providers & Hospitals : Roe-based hospitals and diagnostic centers need market intelligence to evaluate NGS service investments, understand adoption trends, and benchmark against regional competitors.
- Sequencing Service Providers : NGS companies seeking to enter or expand in Roe require detailed market sizing, growth forecasts, and customer segment analysis to develop targeted market strategies.
- Pharmaceutical & Biotech Companies : Roe-focused pharma firms need insights into local genomic research capabilities, clinical trial infrastructure, and biomarker discovery services to optimize R&D investments.
- Healthcare Investors & Consultants : Investment firms and management consultants evaluating Roe's healthcare sector require validated market data and growth projections to assess portfolio opportunities and valuations.
- Government & Policy Makers : Roe's healthcare authorities and policymakers need market intelligence to inform precision medicine initiatives, genomic infrastructure investments, and regulatory framework development.
Key Companies in the Roe Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market-Specific Growth Intelligence : Gain detailed insights into Roe's unique NGS market dynamics, including localized adoption patterns, regulatory environment, and competitive landscape specific to this geography.
- Investment Decision Support : Make informed strategic decisions about market entry, expansion, or partnership opportunities in Roe with validated market size data and 21% CAGR projections through 2022.
- Competitive Positioning Analysis : Understand Roe's healthcare infrastructure, institutional capabilities, and service provider landscape to identify competitive advantages and market gaps for NGS service offerings.
- Segment-Specific Opportunity Mapping : Identify high-growth segments within Roe's market including clinical diagnostics, pharmaceutical research, and academic institutions driving the majority of sequencing service demand.
- Strategic Planning & Forecasting : Leverage comprehensive market data to develop accurate business forecasts, resource allocation strategies, and long-term growth plans tailored to Roe's NGS services market trajectory.
Frequently asked questions
What is the market size of NGS Services in Roe?
Roe's NGS Services Market was valued at $58.7 million in 2017 and is forecasted to reach $152.1 million by 2022.
What is the CAGR for NGS Services in Roe?
Roe's NGS Services Market is expected to grow at a compound annual growth rate of 21.0% from 2017 to 2022.
What factors are driving NGS market growth in Roe?
Roe's NGS market growth is driven by increased precision medicine adoption, rising healthcare investments, growing genetic disorder prevalence, and modernization of diagnostic infrastructure.
Which sectors in Roe are adopting NGS services?
Roe's NGS services are being adopted across clinical diagnostics, research institutions, pharmaceutical development, and personalized medicine initiatives.
How does Roe's NGS market compare to Europe?
Roe represents a significant growth market within Europe's NGS landscape, with a 21.0% CAGR reflecting strong regional demand for advanced genomic technologies.
RESEARCH METHODOLOGY
This study on the Next-Generation Sequencing (NGS) Services Market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the Next-Generation Sequencing (NGS) Services Market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global Next-Generation Sequencing (NGS) Services Market , which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Next-Generation Sequencing (NGS) Services Market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Next-Generation Sequencing (NGS) Services Market . These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the Next-Generation Sequencing (NGS) Services Market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global Next-Generation Sequencing (NGS) Services Market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the next-generation sequencing market
- To benchmark players within the Next-Generation Sequencing (NGS) Services Market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
